Excludes commercial-in-confidence projects.
Research since 2008 is shown below. To see earlier years visit ORCID
Open access indicates that an output is open access.
Ebert, LM, Yu, W, Gargett, T, Toubia, J, Kollis, PM, Tea, MN, Ebert, BW, Bonder, CS, Oksdath Mansilla, M, Scheer, KG, Perrin, SL, Pitson, SM, Gomez, GA & Brown, MP and 8 other authors 2020, 'Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy', Clinical and Translational Immunology, vol. 9, no. 10, article no. e1191, pp. 1-24.
Open access 4
Brown, MP, Ebert, LM & Gargett, T 2019, 'Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma', Clinical and Translational Immunology, vol. 8, no. 5, article no. e1050, pp. 1-20.
Open access 13 13 5
Gargett, T, Truong, N, Ebert, LM, Yu, W & Brown, MP 2019, 'Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype', Cytotherapy, vol. 21, no. 5, pp. 593-602.
6 7 2
Mencel, J, Gargett, T, Karanth, N, Pokorny, A, Brown, MP & Charakidis, M 2019, 'Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma', Asia Pacific Journal of Clinical Oncology, vol. 15, no. 6, pp. 383-386.
Zhang, P, Raju, J, Ullah, MA, Au, R, Gargett, T, Brown, MP & Tey, SK 22 total authors 2019, 'Phase I trial of inducible caspase 9 T cells in adult stem cell transplant demonstrates massive clonotypic proliferative potential and long-term persistence of transgenic T cells', Clinical Cancer Research, vol. 25, no. 6, pp. 1749-1755.
Open access 5 5 22
Ebert, LM, Yu, W, Gargett, T & Brown, MP 2018, 'Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology', Biochemical Society Transactions, vol. 46, no. 2, pp. 391-401.
10 11 5
Gargett, T, Abbas, MN, Rolan, P, Price, JD, Gosling, KM, Ferrante, A, Ruszkiewicz, A, Atmosukarto, II, Altin, J, Parish, CR & Brown, MP 2018, 'Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma', Cancer Immunology Immunotherapy, vol. 67, no. 9, pp. 1461-1472.
Open access 17 16 3
Gargett, T, Yu, W, Dotti, G, Yvon, ES, Christo, SN, Hayball, JD, Lewis, ID, Brenner, MK & Brown, MP 2016, 'GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade', Molecular Therapy, vol. 24, no. 6, pp. 1135-1149.
Open access 134 129 8
Gargett, T & Brown, MP 2015, 'Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2', Cytotherapy, vol. 17, no. 4, pp. 487-495.
59 54 18
Gargett, T, Fraser, CK, Dotti, G, Yvon, ES & Brown, MP 2015, 'BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro', Journal of Immunotherapy, vol. 38, no. 1, pp. 12-23.
20 21 1
Gargett, T & Brown, M 2014, 'The inducible caspase-9 suicide gene system as a 'safety switch' to limit on-target, off-tumor toxicities of chimeric antigen receptor T-cells', Frontiers in Pharmacology, vol. 5, article no. 235, pp. 1-7.
Open access 154 142 21
Gargett, T, Bruber-Bauk, B, Garrod, T, Yu, W, Miller, DS, Major, L, Wesselingh, S, Suhrbier, A & Gowans, E 2014, 'Induction of antigen-positive cell death by the expression of Perforin, but not DTa, from a DNA vaccine enhances the immune response', Immunology and Cell Biology, vol. 92, no. 4, pp. 359-367.
21 21 27
Gargett, T, Grubor-Bauk, B, Miller, D, Garrod, T, Yu, S, Wesselingh, S, Suhrbier, A & Gowans, EJ 2014, 'Increase in DNA vaccine efficacy by virosome delivery and co-expression of a cytolytic protein', Clinical and Translational Immunology, vol. 3, article no. e18, pp. 1-7.
Open access 15 2
Garrod, T, Grubor-Bauk, B, Yu, S, Gargett, T & Gowans, EJ 2014, 'Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency', Human Vaccines and Immunotherapeutics, vol. 10, no. 9, pp. 2679-2683.
Open access 8 9 1
Garrod, TJ, Bruber-Bauk, B, Gargett, T, Li, Y, Miller, DS, Wenbo, Y, Major, L, Burrell, CJ, Wesselingh, S, Suhrbier, A & Gowans, EJ 2014, 'DNA vaccines encoding membrane-bound or secreted forms of heat shock protein 70 exhibit improved potency', European Journal of Immunology, vol. 44, no. 7, pp. 1992-2002.
Open access 19 17 1
Garrod, TJ, Gargett, T, Yu, W, Major, L, Burrell, CJ, Wesselingh, S, Suhrbier, A, Grubor-Bauk, B & Gowans, EJ 2014, 'Loss of long term protection with the inclusion of HIV pol to a DNA vaccine encoding gag', Virus Research, vol. 192, pp. 25-33.
5 5 1
Brown, CY, Sadlon, T, Gargett, T, Melville, E, Zhang, R, Drabsch, Y, Ling, M, Strathdee, CA, Gonda, TJ & Barry, SC 2010, 'Robust, reversible gene knockdown using a single lentiviral short hairpin RNA vector', Human Gene Therapy, vol. 21, no. 8, pp. 1005-1017.
Open access 25 27
External engagement & recognition
|Amgen Inc||UNITED STATES|
|Australian National University||AUSTRALIA|
|Baylor College of Medicine||UNITED STATES|
|Houston Methodist Hospital||UNITED STATES|
|Institute of Medical and Veterinary Science||AUSTRALIA|
|Lipotek Pty Ltd||AUSTRALIA|
|QIMR Berghofer Medical Research Institute||AUSTRALIA|
|Queensland Institute of Medical Research||AUSTRALIA|
|Royal Adelaide Hospital||AUSTRALIA|
|Royal Darwin Hospital||AUSTRALIA|
|South Australian Health and Medical Research Institute (SAHMRI)||AUSTRALIA|
|University of Adelaide||AUSTRALIA|
|University of North Carolina at Chapel Hill||UNITED STATES|
|University of Queensland||AUSTRALIA|
|University of South Australia||AUSTRALIA|
|University of Texas||UNITED STATES|
|Women and Children's Health Research Institute||CANADA|